Showing results (261-270 of 334) with videos related to

Sort By:
Pageof 34
Journal of Hypertension|February 8, 2017
Side effects and tolerability of combination blood pressure lowering according to blood pressure levels: an analysis of the PROGRESS and ADVANCE trialsEmily R Atkins, Yoichiro Hirakawa, Abdul Salam, et al.
BMJ (Clinical Research Ed.)|May 29, 2014
Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary careVanessa Selak, C Raina Elley, Chris Bullen, et al.
Lancet (London, England)|March 18, 2015
Worldwide access to treatment for end-stage kidney disease: a systematic reviewThaminda Liyanage, Toshiharu Ninomiya, Vivekanand Jha, et al.
Hypertension (Dallas, Tex. : 1979)|September 4, 2024
Use and Cost Patterns of Antihypertensive Medications in the United States From 1996 to 2021Joshua A Jacobs, Anthony Rodgers, Brandon K Bellows, et al.
JAMA|September 23, 2015
Effect of Lifestyle-Focused Text Messaging on Risk Factor Modification in Patients With Coronary Heart Disease: A Randomized Clinical TrialClara K Chow, Julie Redfern, Graham S Hillis, et al.
BMJ Open|February 17, 2021
Prospective meta-analysis protocol on randomised trials of renin-angiotensin system inhibitors in patients with COVID-19: an initiative of the International Society of HypertensionSonali Rukshana Gnanenthiran, Claudio Borghi, Dylan Burger, et al.
BMJ Open|August 24, 2024
Randomised controlled decentralised feasibility trial of a fixed low-dose combination antihypertensive drug strategy to attenuate cognitive decline in high-risk adultsCheryl Carcel, Lauren Clancy, Katie Harris, et al.
Heart (British Cardiac Society)|September 16, 2025
Predicting cardiovascular events from routine mammograms using machine learningJennifer Yvonne Barraclough, Ziba Gandomkar, Robert A Fletcher, et al.
The Lancet. HIV|March 30, 2018
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trialJean-Michel Molina, Kathleen Squires, Paul E Sax, et al.
International Journal for Equity in Health|June 25, 2017
Healthcare expenditure on Indigenous and non-Indigenous Australians at high risk of cardiovascular diseaseBlake Angell, Tracey-Lea Laba, Tom Lung, et al.
Pageof 34